Disease-association of different killer cell immunoglobulin-like receptors (KIR) and HLA-C gene combinations in reactive arthritis

References

• Chan HW, Kurago ZB, Stewart CA, Wilson MJ, Martin MP, Mace BE, et al. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J Exp Med. 2003;197(2):245–55.
   PubMed Web of Science ®Google Scholar
• Martin AM, Kulski JK, Gaudieri S, Witt CS, Freitas EM, Trowsdale J, et al. Comparative genomic analysis, diversity and evolution of two KIR haplotypes A and B. Gene. 2004;335:121–31.
   PubMed Web of Science ®Google Scholar
• Martin MP, Bashirova A, Traherne J, Trowsdale J, Carrington M. Cutting edge: expansion of the KIR locus by unequal crossing over. J Immunol. 2003;171(5):2192–5.
   PubMed Web of Science ®Google Scholar
• Marsh SG, Parham P, Dupont B, Geraghty DE, Trowsdale J, Middleton D, et al. Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Tissue Antigens. 2003;62(1):79–86.
   PubMedGoogle Scholar
• Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005;5(3):201–14.
   PubMed Web of Science ®Google Scholar
• Rajalingam R. Killer cell immunoglobulin-like receptors influence the innate and adaptive immune responses. Iran J Immunol. 2007;4(2):61–78.
   PubMedGoogle Scholar
• Long BR, Ndhlovu LC, Oksenberg JR, Lanier LL, Hecht FM, Nixon DF, et al. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol. 2008;82(10):4785–92.
   PubMed Web of Science ®Google Scholar
• Deng L, Mariuzza RA. Structural basis for recognition of MHC and MHC-like ligands by natural killer cell receptors. Semin Immunol. 2006;18(3):159–66.
   PubMed Web of Science ®Google Scholar
• Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002;20:217–51.
   PubMed Web of Science ®Google Scholar
• Du Z, Gjertson DW, Reed EF, Rajalingam R. Receptor-ligand analyses define minimal killer cell Ig-like receptor (KIR) in humans. Immunogenetics. 2007;59(1):1–15.
   PubMed Web of Science ®Google Scholar
• Naumova E, Mihaylova A, Ivanova M, Mihailova S. Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma. Cancer Immunol Immunother. 2007;56(1):95–100.
   PubMed Web of Science ®Google Scholar
• Romero V, Azocar J, Zuniga J, Clavijo OP, Terreros D, Gu X, et al. Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome. Mol Immunol. 2008;45(9):2429–36.
   PubMed Web of Science ®Google Scholar
• Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet. 2002;31(4):429–34.
   PubMed Web of Science ®Google Scholar
• Gao X, Jiao Y, Wang L, Liu X, Sun W, Cui B, et al. Inhibitory KIR and specific HLA-C gene combinations confer susceptibility to or protection against chronic hepatitis B. Clin Immunol. 2010;137(1):139–46.
   PubMed Web of Science ®Google Scholar
• Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (New York, NY). 2004;305(5685):872–4.
   Google Scholar
• Momot T, Koch S, Hunzelmann N, Krieg T, Ulbricht K, Schmidt RE, et al. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum. 2004;50(5):1561–5.
   PubMedGoogle Scholar
• Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, Weyand CM, et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med. 2001;193(10):1159–67.
   PubMed Web of Science ®Google Scholar
• Naumova E, Mihaylova A, Stoitchkov K, Ivanova M, Quin L, Toneva M. Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals. Cancer Immunol Immunother. 2005;54(2):172–8.
   PubMed Web of Science ®Google Scholar
• Saito S, Takeda Y, Sakai M, Nakabayahi M, Hayakawa S. The incidence of pre-eclampsia among couples consisting of Japanese women and Caucasian men. J Reprod Immunol. 2006;70(1–2):93–8.
   PubMed Web of Science ®Google Scholar
• Braun J, Sieper J. The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol. 1996;8(4):275–87.
   PubMedGoogle Scholar
• Yu D, Kuipers JG. Role of bacteria and HLA-B27 in the pathogenesis of reactive arthritis. Rheum Dis Clin N Am. 2003;29(1):21–36.
   PubMed Web of Science ®Google Scholar
• Kuipers JG, Zeidler H, Kohler L. How does Chlamydia cause arthritis? Rheum Dis Clin N Am. 2003;29(3):613–29.
   PubMed Web of Science ®Google Scholar
• Bas S, Neff L, Vuillet M, Spenato U, Seya T, Matsumoto M, et al. The proinflammatory cytokine response to Chlamydia trachomatis elementary bodies in human macrophages is partly mediated by a lipoprotein, the macrophage infectivity potentiator, through TLR2/TLR1/TLR6 and CD14. J Immunol. 2008;180(2):1158–68.
   PubMed Web of Science ®Google Scholar
• Gaston JS, Deane KH, Jecock RM, Pearce JH. Identification of 2 Chlamydia trachomatis antigens recognized by synovial fluid T cells from patients with Chlamydia induced reactive arthritis. J Rheumatol. 1996;23(1):130–6.
   PubMed Web of Science ®Google Scholar
• Sieper J. Pathogenesis of reactive arthritis. Curr Rheumatol Rep. 2001;3(5):412–8.
   PubMedGoogle Scholar
• Bensinger SJ, Bandeira A, Jordan MS, Caton AJ, Laufer TM. Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4(+)25(+) immunoregulatory T cells. J Exp Med. 2001;194(4):427–38.
   PubMed Web of Science ®Google Scholar
• Singh R, Aggarwal A, Misra R. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol. 2007;34(11):2285–90.
   PubMed Web of Science ®Google Scholar
• Colbert RA. HLA-B27 misfolding: a solution to the spondyloarthropathy conundrum? Mol Med Today. 2000;6(6):224–30.
   PubMedGoogle Scholar
• Jiao YL, Ma CY, Wang LC, Cui B, Zhang J, You L, et al. Polymorphisms of KIRs gene and HLA-C alleles in patients with ankylosing spondylitis: possible association with susceptibility to the disease. J Clin Immunol. 2008;28(4):343–9.
   PubMed Web of Science ®Google Scholar
• Jiao YL, Zhang BC, You L, Li JF, Zhang J, Ma CY, et al. Polymorphisms of KIR gene and HLA-C alleles: possible association with susceptibility to HLA-B27-positive patients with ankylosing spondylitis. J Clin Immunol. 2010;30(6):840–4.
   PubMed Web of Science ®Google Scholar
• Martin MP, Nelson G, Lee JH, Pellett F, Gao X, Wade J, et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol. 2002;169(6):2818–22.
   PubMed Web of Science ®Google Scholar
• Nelson GW, Martin MP, Gladman D, Wade J, Trowsdale J, Carrington M. Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol. 2004;173(7):4273–6.
   PubMed Web of Science ®Google Scholar
• Kingsley G, Sieper J. Third International Workshop on Reactive Arthritis. 23–26 September 1995, Berlin, Germany. Report and abstracts. Ann Rheum Dis. 1996;55(8):564–84.
   PubMed Web of Science ®Google Scholar
• Pacheco-Tena C, Burgos-Vargas R, Vazquez-Mellado J, Cazarin J, Perez DJA. A proposal for the classification of patients for clinical and experimental studies on reactive arthritis. J Rheumatol. 1999;26(6):1338–46.
   PubMed Web of Science ®Google Scholar
• Hou YF, Zhang YC, Jiao YL, Wang LC, Li JF, Pan ZL, et al. Disparate distribution of activating and inhibitory killer cell immunoglobulin-like receptor genes in patients with systemic lupus erythematosus. Lupus. 2010;19(1):20–6.
   PubMed Web of Science ®Google Scholar
• Single RM, Martin MP, Gao X, Meyer D, Yeager M, Kidd JR, et al. Global diversity and evidence for coevolution of KIR and HLA. Nat Genet. 2007;39(9):1114–9.
   PubMed Web of Science ®Google Scholar
• Bunce M, O'Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris PJ, et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens. 1995;46(5):355–67.
   PubMedGoogle Scholar
• Hoglund P, Ohlen C, Carbone E, Franksson L, Ljunggren HG, Latour A, et al. Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice. Proc Natl Acad Sci USA. 1991;88(22):10332–6.
   PubMed Web of Science ®Google Scholar
• Diefenbach A, Raulet DH. Strategies for target cell recognition by natural killer cells. Immunol Rev. 2001;181:170–84.
   PubMed Web of Science ®Google Scholar
• Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, D'Andrea A, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1997;7(6):739–51.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633–40.
   PubMed Web of Science ®Google Scholar
• Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood. 2005;105(11):4416–23.
   PubMed Web of Science ®Google Scholar
• Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436(7051):709–13.
   PubMed Web of Science ®Google Scholar
• Namekawa T, Snyder MR, Yen JH, Goehring BE, Leibson PJ, Weyand CM, Goronzy JJ. Killer cell activating receptors function as costimulatory molecules on CD4 + CD28null T cells clonally expanded in rheumatoid arthritis. J Immunol. 2000;165(2):1138–45.
   PubMed Web of Science ®Google Scholar
• Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7− CD28− T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest. 1996;97(9):2027–37.
   PubMed Web of Science ®Google Scholar
• van Bergen J, Thompson A, van der Slik A, Ottenhoff TH, Gussekloo J, Koning F. Phenotypic and functional characterization of CD4 T cells expressing killer Ig-like receptors. J Immunol. 2004;173(11):6719–26.
   PubMed Web of Science ®Google Scholar
• Basu D, Liu Y, Wu A, Yarlagadda S, Gorelik GJ, Kaplan MJ, et al. Stimulatory and inhibitory killer Ig-like receptor molecules are expressed and functional on lupus T cells. J Immunol. 2009;183(5):3481–7.
   PubMed Web of Science ®Google Scholar
• Snyder MR, Nakajima T, Leibson PJ, Weyand CM, Goronzy JJ. Stimulatory killer Ig-like receptors modulate T cell activation through DAP12-dependent and DAP12-independent mechanisms. J Immunol. 2004;173(6):3725–31.
   PubMed Web of Science ®Google Scholar
• Holm SJ, Sakuraba K, Mallbris L, Wolk K, Stahle M, Sanchez FO. Distinct HLA-C/KIR genotype profile associates with guttate psoriasis. J Invest Dermatol. 2005;125(4):721–30.
   PubMed Web of Science ®Google Scholar
• Jobim M, Jobim LF, Salim PH, Cestari TF, Toresan R, Gil BC, et al. A study of the killer cell immunoglobulin-like receptor gene KIR2DS1 in a Caucasoid Brazilian population with psoriasis vulgaris. Tissue Antigens. 2008;72(4):392–6.
   PubMedGoogle Scholar
• Fauriat C, Ivarsson MA, Ljunggren HG, Malmberg KJ, Michaelsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood. 2010;115(6):1166–74.
   PubMed Web of Science ®Google Scholar
• Majorczyk E, Pawlik A, Łuszczek W, Nowak I, Wiśniewski A, Jasek M, et al. Associations of killer cell immunoglobulin-like receptor genes with complications of rheumatoid arthritis. Genes Immun. 2007;8(8):678–83.
   PubMed Web of Science ®Google Scholar
• Kimoto Y, Horiuchi T, Tsukamoto H, Kiyohara C, Mitoma H, Uchino A, et al. Association of killer cell immunoglobulin-like receptor 2DL5 with systemic lupus erythematosus and accompanying infections. Rheumatology (Oxford, England). 2010;49(7):1346–53.
   PubMed Web of Science ®Google Scholar
• Estefania E, Flores R, Gomez-Lozano N, Aguilar H, Lopez-Botet M, Vilches C. Human KIR2DL5 is an inhibitory receptor expressed on the surface of NK and T lymphocyte subsets. J Immunol. 2007;178(7):4402–10.
   PubMed Web of Science ®Google Scholar
• Vilches C, Rajalingam R, Uhrberg M, Gardiner CM, Young NT, Parham P. KIR2DL5, a novel killer-cell receptor with a D0-D2 configuration of Ig-like domains. J Immunol. 2000;164(11):5797–804.
   PubMed Web of Science ®Google Scholar
• Ahlenstiel G, Martin MP, Gao X, Carrington M, Rehermann B. Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J Clin Invest. 2008;118(3):1017–26.
   PubMed Web of Science ®Google Scholar